Shop by goal

Popular compounds

GHK-Cu Copper Peptide

Retatrutide

Research resources

Semaglutide Peptide de recherche (NN9535)

Semaglutide est un agoniste du récepteur GLP-1 à action prolongée, doté d'un squelette peptidique modifié et d'une chaîne latérale d'acide gras conçue pour favoriser la liaison à l'albumine. Il est largement étudié comme référence de pharmacologie du récepteur GLP-1 pour la signalisation intracellulaire et la recherche métabolique. New-U GLP1-RC-SM est proposé comme matériel de recherche en laboratoire en concentrations au choix. Consultez le rapport publié du produit et le coffret sélectionné ; le matériel fourni n'est pas un médicament approuvé et n'est pas présenté comme équivalent à un produit de marque.

For laboratory research only. Not an approved medicine or material for human or veterinary use.

Domaines de recherche publiés

🧬 Pharmacologie des récepteurs

📊 Critères métaboliques

🩸 Critères glycémiques

Product features

Certificate of Analysis Janoshik Analytical report #63609 Tested Apr 2025. Published online, not packed with orders.

Measured purity 99.358% Result Janoshik Analytical reported for the sample tested.

Vial strengths 2 mg · 5 mg · 10 mg · +4 more 7 strengths, all in stock. Pick one in the selector.

View all product features

Formats Single vial · 10-vial pack Price per vial and pack total update with your selection.

This strength is out of stock. Pick another strength, or check back soon — restocks are frequent.

Available in 7 vial strengths, from 2 mg to 50 mg

Dispatched within 24 hours of confirmed payment on business days, shipped worldwide

Third-party tested by Janoshik Analytical

99.358% purity on the latest published report

Purity test report: PDF download

Semaglutide Peptide de recherche (NN9535)

Compare pack sizes

Tap a pack to select it

Single Vials (7)

Buy the 10-pack - save 66%/mg. Single vials welcome — checkout needs 3+ vials or any 10-vial pack - build a custom vial pack

Lab-direct quality — full packs or single-vial samples

Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and verified to >99% HPLC purity with a published batch Certificate of Analysis. View the batch Certificate of Analysis → Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.

Order a sealed 10-vial research pack , or mix single vials across compounds and strengths — an order needs at least 3 single vials in total, or any 10-vial pack. Same source, same purity specification — scaled to whatever your research needs.

GLP1-RC-SM Certificate of Analysis

GLP1-RC-SM material is analysed by an independent laboratory, and the resulting Certificate of Analysis is published online. A certificate reports what was measured in the sample submitted; vials are not batch-marked, so it is not matched to a particular vial or order.

New-U GLP1-RC-SM certificate evidence

Catalogue identifier: GLP1-RC-SM

Independent testing laboratory, report number and test date

Measured purity for the sample analysed

Certificate of Analysis at /coa/semaglutide; the method and any identity result are stated on the report

Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Published scientific literature

External experimental and clinical studies

Receptor pharmacology and pharmacokinetics

Protocol-defined trial endpoints and timepoints

Adverse events recorded by investigators

Registered trial records and peer-reviewed citations (DOI / PMID / NCT)

Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-SM research material.

Domaines de recherche publiés

Les études publiées examinent l’activité des récepteurs, la pharmacocinétique et des critères métaboliques, glycémiques, cardiovasculaires et rénaux définis par protocole. Les résumés ci-dessous rapportent ce que les chercheurs ont mesuré dans ces études externes et ne constituent pas des instructions d’utilisation du matériel de recherche fourni ici.

Pharmacologie des récepteurs

Agonisme GLP-1R aux sites pancréatiques, gastro-intestinaux et hypothalamiques, caractérisé dans des études publiées sur les récepteurs.

Critères métaboliques

Variation de la masse corporelle par rapport à la valeur initiale définie par protocole, mesurée dans le programme STEP.

Critères glycémiques

HbA1c comme critère défini par protocole, mesuré dans l’ensemble du programme SUSTAIN sur le diabète.

Critères cardiovasculaires et rénaux

Événements cardiovasculaires indésirables majeurs (SELECT) et événements de maladie rénale (FLOW), mesurés dans des essais randomisés de résultats.

Hepatic Histology Endpoints

Biopsy-assessed steatohepatitis and fibrosis endpoints in metabolic dysfunction-associated steatohepatitis (ESSENCE), measured in a randomised phase 3 trial.

Pharmacocinétique

Exposition systémique, biodisponibilité et semivie apparente, d'après une caractérisation pharmacocinétique publiée.

Scientific Overview

In short: GLP1-RC-SM est un composé de recherche agoniste GLP-1R, couramment appelé « Sema » dans les communautés de recherche.

Key research facts

Pharmacologie des récepteurs : activité agoniste GLP-1R caractérisée dans des études publiées de pharmacologie in-vitro et clinique

Peptide de 31 acides aminés présentant 94% d’homologie de séquence avec le GLP-1(7-37) humain natif

Substitution Aib8 étudiée pour la résistance à DPP-IV ; substitution Arg34 étudiée pour une stabilité peptidique modifiée

Modification C18 fatty-diacid/mini-PEG étudiée comme facteur contribuant à une exposition systémique prolongée (demi-vie apparente d’environ 7 jours)

STEP-1 RCT (NEJM 2021, PMID 33567185), bras 2.4 mg : les investigateurs ont rapporté une variation moyenne du poids corporel par rapport à l'inclusion de −14.9% à la semaine 68

These points summarise lab themes, not human outcomes.

Les travaux publiés caractérisent la pharmacologie des récepteurs, les modifications structurelles et le profil pharmacocinétique de cette classe de composés, parallèlement à des critères définis par protocole étudiés dans des programmes cliniques enregistrés.

La vérification des lots New-U et la littérature externe constituent deux ensembles de preuves distincts : les analyses de lot établissent l’identité analytique et la pureté du matériau testé ; les études publiées décrivent leurs propres matériaux et protocoles expérimentaux.

Architecture moléculaire

Un peptide de 31 acides aminés partageant 94% de sa séquence avec le GLP-1 humain natif, une hormone intestinale libérée après les repas.

Pharmacologie des récepteurs

Les études de pharmacologie des récepteurs caractérisent l’agonisme GLP-1R avec sécrétion de insulin dépendante du glucose, suppression de glucagon, retard de la vidange gastrique et signalisation des circuits hypothalamiques de l’appétit. Tableau complet des voies : Receptor Pharmacology ci-dessous.

Modifications structurelles

GLP-1 natif serait dégradé en environ deux minutes in vivo. Les travaux structurels publiés attribuent l’exposition systémique prolongée de ce composé à trois modifications conçues : une substitution Aib8, une substitution Arg34 et un C18 fatty diacid lié à Lys26, étudié comme facteur de liaison à l’albumine.

Pharmacocinétique publiée

La demi-vie apparente d'élimination est rapportée à environ 7 jours, avec une biodisponibilité sous-cutanée d'environ 89 %. Voir la section « Pharmacocinétique » ci-dessous.

Recherche clinique

Les résultats publiés résumés sur cette page concernent des études cliniques externes du médicament de référence et leurs matériels et protocoles respectifs. Ils n’établissent pas la sécurité, l’efficacité ou l’équivalence clinique du matériel New-U GLP1-RC-SM.

Références principales

Les publications évaluées par les pairs et les dossiers d’essais enregistrés sont listés intégralement, avec les identifiants DOI/PMID/NCT, dans Source References ci-dessous.

At a glance

Mechanism and receptors Published experimental work characterises GLP-1R agonist activity, with an albumin-binding structural modification investigated as a contributor to prolonged systemic exposure.

Clinical research SELECT cardiovascular-outcomes RCT — 17,604 participants (NEJM 2023; PMID 37952131); FLOW kidney-outcomes RCT (NEJM 2024; PMID 38785209); SOUL oral cardiovascular-outcomes RCT (NEJM 2025; PMID 40162642); SUSTAIN diabetes programme.

Molecular characteristics Molecular weight 4,113.58 Da.

Pharmacokinetics Half-life: Apparent elimination half-life reported at approximately 7 days (165–184 h); steady-state exposure reported after 4–5 weeks.

Evidence maturity Tier 1: Human clinical — The evidence tier describes the published literature on Semaglutide, the scientific subject, and specifically on the finished pharmaceutical studied in those trials.

Analytical verification Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Research limitations Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-SM research material.

Receptor Pharmacology

Published experimental work characterises GLP-1R agonist activity, with an albumin-binding structural modification investigated as a contributor to prolonged systemic exposure.

Pathway Effect Why it matters GLP-1R (pancreatic β-cells) Agonist activity characterised in receptor pharmacology studies Glucose-dependent insulin secretion is the defining incretin property recorded in the literature GLP-1R (pancreatic α-cells) Agonist activity characterised experimentally Glucagon suppression recorded as a measured pharmacodynamic endpoint GLP-1R (gastrointestinal tract) Agonist activity characterised experimentally Delayed gastric emptying recorded as a measured pharmacodynamic endpoint GLP-1R (hypothalamus) POMC/CART activation and AgRP/NPY inhibition characterised in preclinical models The central signalling arm measured in energy-intake studies Albumin-binding modification C18 fatty diacid via a γGlu/mini-PEG spacer; >99% plasma protein binding reported Investigated as a contributor to prolonged systemic exposure (~7-day apparent half-life) Proteolytic stability Aib8 and Arg34 substitutions Structural modifications investigated for altered peptide stability against DPP-IV

Deeper dive for scientific readers

Lau et al. (J Med Chem, 2015; DOI 10.1021/acs.jmedchem.5b00726) describe three modifications relative to native GLP-1(7-37): an Aib substitution at position 8, an Arg substitution at position 34, and Lys26 acylation with a C18 fatty diacid via a γGlu/mini-PEG (AEEA) spacer. The fatty chain is reported to bind serum albumin reversibly, which the authors attribute the extended circulating exposure to. Published pharmacokinetic work reports steady-state exposure after 4–5 weeks of the protocol-defined weekly administration, with elimination via proteolytic cleavage and β-oxidation of the fatty chain and no CYP-mediated interactions. Every figure here is an observation recorded in the cited external study of the reference medicine.

Common Questions People Are Asking

Qu'est-ce que Semaglutide dans la recherche scientifique ?

Semaglutide est un agoniste du récepteur GLP-1 de 31 acides aminés caractérisé dans des recherches publiées de pharmacologie des récepteurs et des recherches cliniques. Il est approuvé comme médicament dans certaines juridictions sous des noms de marque d'autres fabricants; le matériel fourni ici n'est pas ce produit pharmaceutique fini.

Qu'est-ce que GLP1-RC-SM ?

GLP1-RC-SM est l’identifiant de catalogue New-U pour le matériel de recherche en laboratoire proposé dans ce profil de recherche. Ce n’est pas un médicament, un traitement, un générique pharmaceutique ou un produit thérapeutique ; il n’est équivalent à aucun produit clinique ou commercial et n’est pas proposé pour un usage humain ou vétérinaire.

Quels systèmes de récepteurs sont examinés dans la recherche sur Semaglutide ?

Les travaux publiés caractérisent l’activité agoniste au GLP-1 receptor dans quatre contextes tissulaires : cellules β pancréatiques (sécrétion de insulin dépendante du glucose), cellules α pancréatiques (suppression de glucagon), tractus gastro-intestinal (retard de la vidange gastrique) et circuits hypothalamiques (activation POMC/CART, inhibition AgRP/NPY dans des modèles précliniques). Les travaux structurels étudient également la modification C18 fatty-diacid de liaison à l’albumine et la substitution Aib8 pour une stabilité protéolytique modifiée.

Quels tests analytiques accompagnent GLP1-RC-SM ?

Le certificat d'analyse publié de GLP1-RC-SM provient d'un laboratoire d'analyse indépendant et indique le laboratoire indépendant, le numéro de rapport, la pureté mesurée et la date de l'essai pour l'échantillon analysé ; la méthode et tout résultat d'identité figurent sur le rapport lui-même. Les flacons ne portent pas de marquage de lot : un certificat décrit donc l'échantillon testé, et non un flacon ou une commande en particulier. L'analyse de lot rend compte de l'identité et de la pureté de l'échantillon testé. Elle n'établit ni la stérilité, ni le taux d'endotoxines ou de métaux lourds, ni l'équivalence pharmaceutique, ni aucune propriété clinique.

Où consulter le certificat d'analyse actuel de GLP1-RC-SM ?

Le certificat actuel — laboratoire, numéro de rapport, pureté mesurée et date de l'essai — est publié à l'adresse /coa/semaglutide, avec l'historique des essais du composé.

Que signifie une pureté HPLC >99% ?

Il s’agit d’une valeur de pureté obtenue par reversed-phase high-performance liquid chromatography avec normalisation de l’aire : le pic cible représente plus de 99% de l’aire intégrée totale des pics du chromatogramme pour l’échantillon testé. Cette valeur décrit uniquement la pureté chimique de cet échantillon et ne dit rien de la stérilité, de la teneur en endotoxines, de l’équivalence pharmaceutique ou de toute propriété clinique.

Quels essais cliniques sont référencés sur cette page ?

External studies of the reference medicine: STEP-1 (Wilding et al., NEJM 2021; PMID 33567185), SELECT (Lincoff et al., NEJM 2023; PMID 37952131), FLOW (Perkovic et al., NEJM 2024; PMID 38785209), SOUL (McGuire et al., NEJM 2025; PMID 40162642), STEP UP and STEP UP T2D (Wharton et al. and Lingvay et al., Lancet Diabetes Endocrinol 2025; PMIDs 40961952 and 40961953), ESSENCE (Sanyal et al., NEJM 2025; PMID 40305708), SURMOUNT-5 (Aronne et al., NEJM 2025; PMID 40353578), OASIS 4 (Wharton et al., NEJM 2025; PMID 40934115), evoke / evoke+ (Cummings et al., Lancet 2026; PMID 41865758) and SURPASS-2 (Frías et al., NEJM 2021; PMID 34170647), plus the structural paper by Lau et al. (J Med Chem 2015). Each reported result on this page is attributed to its study, arm and timepoint.

Comment la recherche clinique publiée est-elle distinguée des analyses de lots New-U ?

Ce sont des corpus de preuves distincts. La recherche clinique publiée est un travail externe sur le produit pharmaceutique fini approuvé, mené selon les protocoles propres à ces études ; elle n'établit rien sur le matériel fourni ici. Les essais de certificat de New-U sont un travail analytique sur un échantillon soumis du matériel GLP1-RC-SM : le rapport publié indique le résultat mesuré pour l'échantillon analysé et n'établit rien de clinique. Un certificat d'analyse associé à un article clinique externe ne constitue pas une validation clinique de GLP1-RC-SM.

GLP1-RC-SM est-il identique à un médicament de marque approuvé ?

Non. Les produits de marque semaglutide approuvés sont des produits pharmaceutiques finis, stériles et sur prescription, fabriqués selon cGMP par leurs titulaires d’autorisation de mise sur le marché. GLP1-RC-SM est du matériel de recherche en laboratoire non approuvé fourni sous forme de poudre lyophilisée. Il n’est ni équivalent, ni générique, ni substitut de tout produit approuvé.

En quoi Semaglutide diffère-t-il de GLP-1 natif ?

Les travaux structurels publiés décrivent une homologie de séquence de 94% avec human GLP-1(7-37) natif, plus trois modifications conçues : une substitution Aib en position 8 étudiée pour la résistance à DPP-IV, une substitution Arg en position 34 et un C18 fatty diacid attaché à Lys26. L’acide gras se lierait à l’albumine, ce que la littérature associe à l’allongement de la demi-vie apparente d’environ 2 minutes à environ 7 jours.

Sous quelle forme GLP1-RC-SM est-il fourni ?

GLP1-RC-SM est fourni sous forme de poudre lyophilisée en flacons scellés, en coffrets de recherche scellés de 10 flacons dans les concentrations listées ; le certificat d'analyse est publié sur la page du produit.

Comment le matériel de recherche en laboratoire doit-il être conservé ?

Conserver la poudre lyophilisée dans un congélateur à −20 °C. Si un protocole de laboratoire exige le matériel en solution, maintenir la solution obtenue au réfrigérateur à 1–6 °C, à l'abri de la lumière, et éviter les cycles répétés de réchauffement et refroidissement, qui peuvent dégrader la modification fatty-acid. Les conditions de stockage constituent uniquement des informations de manipulation en laboratoire.

La recherche sur Semaglutide est-elle comparée directement à celle sur Tirzepatide ?

In obesity without type 2 diabetes, one published trial, SURMOUNT-5 (Aronne et al., NEJM 2025; PMID 40353578), was designed as an open-label head-to-head comparison of maximum tolerated doses and reported a larger least-squares mean change from baseline in body weight in the tirzepatide arm than the semaglutide arm at week 72 (−20.2% vs −13.7%). In type 2 diabetes, SURPASS-2 (Frías et al., NEJM 2021; PMID 34170647) compared tirzepatide with semaglutide 1 mg over 40 weeks. Results from separate trials of the two compounds are not head-to-head comparisons and the study designs do not support treating them as such.

Is Semaglutide third-party tested?

Yes. Semaglutide has an independent Janoshik Analytical Certificate of Analysis, which reports 99.358% purity for the sample analysed. The report number and test date are on the certificate, published on this page and on our COA page rather than packed with orders. View the Semaglutide Certificate of Analysis →

Is it legal to buy Semaglutide?

In the United States, Semaglutide is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction - buyers are responsible for compliance in their own region.

Research use only - all claims made on this site are for testing and research use only.

Pharmacokinetics

Half-life Apparent elimination half-life reported at approximately 7 days (165–184 h); steady-state exposure reported after 4–5 weeks Absorption route Study protocols used subcutaneous administration (~89% reported bioavailability); a SNAC-enhanced oral tablet formulation is also described in the literature (~0.4–1% reported oral bioavailability) Bioavailability ~89% subcutaneous; 0.4–1% oral (SNAC co-formulation) reported Metabolism / clearance Proteolytic cleavage of the peptide backbone plus β-oxidation of the C18 fatty-diacid chain reported; no CYP-mediated interactions; ~3% reported excreted unchanged in urine Stability Laboratory handling — lyophilised: −20 °C. Reconstituted: 1–6 °C, protect from light; avoid repeated freeze–thaw Notes Reported volume of distribution ~12.5 L; >99% albumin-bound; clearance ~0.035 L/h. The reversible C18 fatty-diacid/albumin interaction is the protraction mechanism described in the published pharmacokinetic literature. These are observations from external studies of the reference medicine, not a handling or administration instruction for research material.

Research-Observed Effects

STEP-1 RCT (Wilding et al., NEJM 2021; PMID 33567185), overweight/obesity population without diabetes, 2.4 mg arm: investigators reported a mean change from baseline in body weight of −14.9% at week 68 vs −2.4% on placebo (primary estimand, regardless of treatment discontinuation or rescue intervention)

STEP UP RCT (Wharton et al., Lancet Diabetes Endocrinol 2025; PMID 40961952), adults with obesity without diabetes: investigators reported a mean change in body weight at week 72 of −18.7% in the 7.2 mg arm vs −3.9% on placebo (coprimary endpoint, treatment-policy estimand) and vs −15.6% in the 2.4 mg arm (confirmatory secondary comparison); dysaesthesia was recorded more often in the 7.2 mg arm

STEP UP T2D RCT (Lingvay et al., Lancet Diabetes Endocrinol 2025; PMID 40961953), adults with obesity and type 2 diabetes: investigators reported a mean change in body weight of −13.2% in the 7.2 mg arm vs −3.9% on placebo

SURMOUNT-5 RCT (Aronne et al., NEJM 2025; PMID 40353578), open-label head-to-head in obesity without type 2 diabetes, maximum tolerated doses: investigators reported a least-squares mean change in body weight at week 72 of −13.7% with semaglutide vs −20.2% with tirzepatide

OASIS 4 RCT (Wharton et al., NEJM 2025; PMID 40934115), once-daily oral semaglutide 25 mg in overweight/obesity without diabetes: investigators reported a mean change in body weight at week 64 of −13.6% vs −2.2% on placebo

SELECT RCT (Lincoff et al., NEJM 2023; PMID 37952131), 17,604 participants with overweight/obesity and established cardiovascular disease without diabetes: investigators reported a 20% relative reduction in major adverse cardiovascular events

FLOW RCT (Perkovic et al., NEJM 2024; PMID 38785209): investigators reported a 24% relative reduction in major kidney-disease events in a type 2 diabetes CKD population

SOUL RCT (McGuire et al., NEJM 2025; PMID 40162642), oral (SNAC) formulation in high-risk type 2 diabetes: investigators reported a 14% relative reduction in major adverse cardiovascular events

ESSENCE RCT, part 1 interim analysis at week 72 (Sanyal et al., NEJM 2025; PMID 40305708), biopsy-defined MASH with fibrosis stage 2 or 3, 2.4 mg arm: investigators reported resolution of steatohepatitis without worsening of fibrosis in 62.9% vs 34.3% on placebo, and reduction in fibrosis without worsening of steatohepatitis in 36.8% vs 22.4%

evoke and evoke+ RCTs (Cummings et al., Lancet 2026; PMID 41865758), oral semaglutide in early symptomatic Alzheimer's disease: a null result. Investigators reported no slowing of clinical progression on the primary endpoint (change in CDR-SB to week 104) versus placebo in either trial, and both trials were discontinued

SUSTAIN programme: investigators reported HbA1c reductions of ~1.5–1.8% as a protocol-defined endpoint, with a low reported hypoglycaemia rate attributed to glucose-dependent insulin release

Pharmacodynamic studies recorded delayed gastric emptying and reduced postprandial glucose excursions as measured endpoints

Published Research Context

Registered clinical research of the reference medicine used protocol-defined intervention arms. The STEP weight-management programme included arms from 0.25 mg up to a 2.4 mg maintenance level, with a protocol-defined step-up period of roughly 16 weeks, and the later STEP UP trials added a 7.2 mg arm; the SUSTAIN diabetes programme used 0.5–2.0 mg arms. Study protocols used once-weekly subcutaneous administration.

These figures are characteristics of external clinical trials of an approved medicine. They are recorded here as scientific study context and are not a protocol, schedule, starting point or instruction for any use of laboratory research material.

Adverse Events Reported in Published Clinical Research

The events below were recorded by investigators in published clinical trials of the reference medicine. They describe what was observed in those study populations under those protocols; they are not a prediction of, or guidance about, anything a reader may experience.

Common

Nausea — reported as the most frequent event, described as escalation-related and typically transient

Diarrhoea

Vomiting

Constipation

Abdominal pain and decreased appetite recorded as reported adverse events

Rare

Gallbladder events (cholelithiasis, cholecystitis)

Acute pancreatitis, reported infrequently

Injection-site reactions recorded under the study protocols

Thyroid C-cell tumours observed in rodent studies — the basis of the reference medicine’s boxed warning; human relevance reported as unconfirmed

Dose-dependent

Investigators reported gastrointestinal events scaling with arm level and during the protocol-defined step-up period, attenuating at steady state

A transient resting-heart-rate increase of a few bpm was recorded as a measured endpoint

Evidence Tier

Overall: Tier 1: Human clinical

The evidence tier describes the published literature on Semaglutide, the scientific subject, and specifically on the finished pharmaceutical studied in those trials. Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-SM research material.

Tier 1 · Human clinical

STEP-1 weight-management RCT — −14.9% mean change from baseline in body weight at week 68 (NEJM 2021; PMID 33567185)

SELECT cardiovascular-outcomes RCT — 17,604 participants (NEJM 2023; PMID 37952131)

FLOW kidney-outcomes RCT (NEJM 2024; PMID 38785209); SOUL oral cardiovascular-outcomes RCT (NEJM 2025; PMID 40162642); SUSTAIN diabetes programme

STEP UP 7.2 mg RCTs (Lancet Diabetes Endocrinol 2025; PMIDs 40961952, 40961953); ESSENCE MASH RCT (NEJM 2025; PMID 40305708); SURMOUNT-5 head-to-head RCT (NEJM 2025; PMID 40353578); OASIS 4 oral RCT (NEJM 2025; PMID 40934115)

evoke / evoke+ early Alzheimer's disease RCTs — null primary endpoint (Lancet 2026; PMID 41865758)

Certificates, databases & peer-reviewed sources

Last reviewed: 7 November 2026 · New-U Research Compounds

Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. · 2021 · PMID: 33567185 · DOI: 10.1056/NEJMoa2032183

Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. · 2023 · PMID: 37952131 · DOI: 10.1056/NEJMoa2307563

Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med. · 2024 · PMID: 38785209 · DOI: 10.1056/NEJMoa2403347

McGuire DK et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (SOUL). N Engl J Med. · 2025 · PMID: 40162642 · DOI: 10.1056/NEJMoa2501006

Wharton S et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes Endocrinol. · 2025 · PMID: 40961952 · DOI: 10.1016/S2213-8587(25)00226-8

Lingvay I et al. Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D). Lancet Diabetes Endocrinol. · 2025 · PMID: 40961953 · DOI: 10.1016/S2213-8587(25)00225-6

Sanyal AJ et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE). N Engl J Med. · 2025 · PMID: 40305708 · DOI: 10.1056/NEJMoa2413258

Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. · 2025 · PMID: 40353578 · DOI: 10.1056/NEJMoa2416394

Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. · 2021 · PMID: 34170647 · DOI: 10.1056/NEJMoa2107519

Wharton S et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). N Engl J Med. · 2025 · PMID: 40934115 · DOI: 10.1056/NEJMoa2500969

Cummings JL et al. Oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+). Lancet. · 2026 · PMID: 41865758 · DOI: 10.1016/S0140-6736(26)00459-9

Lau J et al. Discovery of the Once-Weekly GLP-1 Analogue Semaglutide. J Med Chem. · 2015 · DOI: 10.1021/acs.jmedchem.5b00726

PubMed: peer-reviewed literature on Semaglutide

ClinicalTrials.gov: registered studies on Semaglutide

Semaglutide: Wikipedia (search)

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Key Characteristics

31-amino-acid peptide, 94% homologous to native human GLP-1(7-37)

GLP-1R agonist activity characterised in receptor-pharmacology studies

Aib8 substitution investigated for DPP-IV resistance

C18 fatty-diacid modification reported to give >99% albumin binding

Apparent elimination half-life reported at approximately 7 days in published pharmacokinetic research

GLP1-RC-SM laboratory research material — analytically verified, >99% HPLC purity

Supplied as lyophilised powder for laboratory research; not the finished pharmaceutical studied in the cited trials

Specifications

Identifiant de catalogue New-U GLP1-RC-SM Sujet scientifique Semaglutide Formule moléculaire C₁₈₇H₂₉₁N₄₅O₅₉ Masse moléculaire 4113.58 Da Récepteur caractérisé GLP-1 receptor (GPCR de classe B) Pureté (analytique) >99% par normalisation de l’aire RP-HPLC Identité (analytique) Indiqué sur le certificat d'analyse publié lorsque le rapport comprend un test d'identité Forme Poudre lyophilisée Demi-vie publiée Environ 7 jours, 165-184 h (recherche pharmacocinétique externe) Conservation Lyophilisé : congélateur à −20 °C. Reconstitué : 1-6 °C, à l'abri de la lumière. Utilisation prévue Laboratory research material. Not for human or veterinary use.

Semaglutide Research — GLP1-RC-SM Laboratory Research Material

Semaglutide is among the most extensively characterised metabolic peptides in the published literature, and the GLP-1 receptor agonist against which later compounds such as tirzepatide and the CagriSema co-formulation are benchmarked in the research record. Published structural work describes how a hormone degraded within minutes in vivo was engineered for prolonged systemic exposure by anchoring it to serum albumin via a C18 fatty-diacid modification.

Published clinical research of the reference medicine reports protocol-defined endpoints: a mean change from baseline in body weight of −14.9% at week 68 in the STEP-1 2.4 mg arm (NEJM 2021), a 20% relative reduction in major adverse cardiovascular events in SELECT (NEJM 2023), a 24% relative reduction in major kidney-disease events in FLOW (NEJM 2024), and a 14% relative reduction in major adverse cardiovascular events with the oral SNAC formulation in SOUL (NEJM 2025). Later trials reported a −18.7% mean change in body weight at week 72 with a 7.2 mg arm in STEP UP (Lancet Diabetes Endocrinol 2025) and histological endpoints in MASH in ESSENCE (NEJM 2025), while the evoke and evoke+ trials of oral semaglutide in early Alzheimer's disease reported no slowing of clinical progression versus placebo (Lancet 2026). Each of those figures belongs to the study, population and timepoint that produced it.

New-U Research Compounds supplies GLP1-RC-SM as lyophilised, analytically verified laboratory research material ; its published independent Certificate of Analysis records the independent laboratory, report number, measured purity and test date for the sample analysed. Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property. Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-SM research material. GLP1-RC-SM is not an approved medicine, is not the finished pharmaceutical studied in the cited trials, and is not offered for human or veterinary use.

Glucagon-like peptide-1 - Wikipedia

GLP-1 receptor agonist - Wikipedia

Customer Reviews

No customer reviews yet - be the first to share your experience.

More in Metabolic Research

Metabolic Research Retatrutide Retatrutide (LY3437943) is an investigational triple GLP-1R / GIPR / GCGR agonist evaluated in registered clinical research. GLP1-RC-RT is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. Retatrutide →

Metabolic Research Tirzepatide Tirzepatide is a dual GIP / GLP-1 receptor agonist characterised in published research, with imbalanced agonism favouring GIPR. GLP1-RC-TZ is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. Tirzepatide →

Metabolic Research Cagrilintide Cagrilintide (AM833), a long-acting acylated amylin analogue and non-selective AMYR/CTR agonist with an extended half-life, studied in amylin-receptor and metabolic research. Cagrilintide →

Metabolic Research Eloralintide Eloralintide (LY3841136), a selective, long-acting amylin receptor agonist with AMY1R-preferring pharmacology, studied in amylin-receptor and metabolic research. Eloralintide →

Metabolic Research Liraglutide Liraglutide is a GLP-1 receptor agonist: a 31-residue analogue of GLP-1(7-37) with an Arg34 substitution and a C16 palmitoyl-γ-glutamate side chain on Lys26 that promotes albumin binding. Liraglutide →

Semaglutide vs related Metabolic Research compounds

Compound Price Purity spec COA Semaglutide from $111 >99% HPLC 1 published batch Retatrutide from $173 >99% HPLC 4 published batches Tirzepatide from $221 >99% HPLC 2 published batches

Semaglutide vs Retatrutide - full comparison

Semaglutide vs Tirzepatide - full comparison

Descriptive catalog comparison for research sourcing decisions - not dosing guidance.

More on Semaglutide

Metabolic Research research compounds

Semaglutide research guide

Semaglutide pricing and packs

Research this compound

Research guide Semaglutide research guide Published experimental work characterises GLP-1R agonist activity, with an albumin-binding structural modification investigated as a… Read the guide →

Compare Compare Semaglutide and Liraglutide Semaglutide vs Liraglutide: mechanism, receptor profile and specifications side by side. Compare →

Analytical evidence View the Semaglutide COA Latest published certificate of analysis (purity and identity), dated 2025-04-30. View the COA →

Part of the Metabolic & GLP-1 research research area — explore related compounds, guides and sources.

From our community

What people say on Facebook

Facebook account deactivated

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research